




ACUITY™ X4
Quadripolar LV Leads

**Boston
Scientific**
Advancing science for life™

New Solutions. Meaningful Outcomes.



The first and only LV leads uniquely designed to promote non-apical pacing options, helping physicians to pace from an optimal site for improved CRT response.



Designed to Help Optimize CRT-response

With multiple tip shapes and unique electrode configurations, ACUIITY™ X4 leads are specifically designed to help you get to the optimal pacing site.

Therapy-based Vector Selection

LV Vector Guide™ helps you choose the most therapeutic vector for pacing based on RV/LV Delay.

Clinically Meaningful Difference in Longevity

The X4 CRT-D is powered by ENDURALIFE™ Battery Technology, which continues to outlast the competition.¹⁻⁴

The X4 CRT System



**Discover more
about ACUIITY X4 leads.**

BostonScientific.com/ACUIITYX4

ACUITY™ X4

Quadripolar LV Leads

Improving Delivery & Optimizing Pacing Performance


IN THE NAVIGATE X4 STUDY:

- Dual fixation mechanisms on ACUITY X4 Spiral models led to stability rates of 99.1%⁵
- Leads experienced a 99.6% phrenic nerve stimulation complication-free rate^{5*}

HALF OF ACUITY X4 SPIRAL LEADS WERE PLACED IN **6 MINUTES OR LESS[†]**

*A PNS complication is defined as a case when a PNS occurrence was not resolvable without surgery.

† LV lead placement time was defined as the time from the LV lead entering the catheter to the first PSA measurement.



Designed to place more electrodes in mid or basal location of the left ventricle, the ACUITY X4 Spiral leads press the proximal electrodes against the vessel wall.

Clinically Meaningful Patient Outcomes

IN THE NAVIGATE X4 STUDY:

Shorter implant time for ACUITY X4 Spiral leads⁵ could mean reduced fluoroscopy time



ACUITY™ X4 LEADS **REQUIRED ZERO REOPERATIONS** DUE TO PACING CAPTURE OR THRESHOLDS⁵

Redefining Quadripolar Pacing to Improve CRT Response

IN THE IDE STUDY:

ACUITY X4 SPIRAL LEADS WERE PROGRAMMED WITH A

PROXIMAL ELECTRODE AS THE PACING CATHODE

77.3%⁵



Discover more about ACUITY X4 leads.

[BostonScientific.com/ACUITYX4](https://www.bostonscientific.com/ACUITYX4)

1. J. Williams, R. Stevenson. Contemporary cardiac resynchronization implantable cardioverter defibrillator battery longevity in a community hospital heart failure cohort. Presented at HFSA 2014. [http://www.onlinejcf.com/article/S1071-9164\(14\)00389-3/fulltext](http://www.onlinejcf.com/article/S1071-9164(14)00389-3/fulltext). Boston Scientific = 53 patients, Medtronic = 28 patients, St. Jude Medical = 10 patients. Four-year survival rate calculated using device replacements for battery depletion as indicated by ERI.
2. Haarbo J, Hjortshøj S, Johansen J, Jorgensen O, Nielsen J, Petersen H. Device Longevity in Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators Differs Between Manufacturers: Data from the Danish ICD Registry. Presented at HRS 2014. <http://ondemand.hrsonline.org/common/presentation-detail.aspx/15/35/1241/9000>. Boston Scientific = 136 patients, Medtronic = 651 patients, St. Jude Medical = 1,587 patients, Bitronik = 369 patients. Time to exchange of the device because of battery depletion or device failure recorded in the Danish ICD Registry was the endpoint. The four-year survival rate for devices in the Danish Registry study was 81.1% for Medtronic and 95.7% for Boston Scientific (P<0.01).
3. Alam M, Munir B, Rattan R, Flanigan S, Adelstein E, Jan S, Saba S. Battery Longevity in Cardiac Resynchronization Therapy Defibrillators. 2013; Europace (2013) doi: 10.1093/europace/eut301. First published online: October 6, 2013. Kaplan Meier curves depicting survival of CRT devices free from battery depletion by device manufacturer. Battery Longevity in Cardiac Medtronic = 416 patients, Boston Scientific = 173 patients, St. Jude Medical = 57 patients. Four-year survival rate calculated using device replacements for battery depletion as indicated by ERI.
4. Ellis C, Markus T, Dickerman D, Orton J, Hassan S, Good E, Okabe T, Greenspon A. Ampere Hour as a Predictor of CRT ICD Pulse Generator Longevity: A Multi-Center Study. Presented at HFSA 2014. [http://www.onlinejcf.com/article/S1071-9164\(14\)00337-6/fulltext](http://www.onlinejcf.com/article/S1071-9164(14)00337-6/fulltext). Ampere Hour (Ah) as a Predictor of CRT ICD Pulse Generator Battery Longevity Study. The five major institutions performing the study include, at Vanderbilt University, Eastside Cardiovascular Medicine, University of Michigan, Thomas Jefferson University, Robert Wood Johnson University Hospital, Cooper Health System and North Ohio Research. Boston Scientific = 266 patients, Medtronic = 542 patients, St. Jude Medical = 149 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.
5. Clinical Summary: NAVIGATE X4 Study 358487-022 EN US 2016-01



ACUIITY™ X4 Quadripolar LV Leads

Indications, Safety, and Warnings
<https://qrco.de/bgrtrl>



AUTOGEN™, AUTOGEN™X4, DYNAGEN™, DYNAGEN™X4, INOGEN™, INOGEN™ X4, ORIGEN™, ORIGEN™X4, INCEPTA™, ENERGEN™, PUNCTUA™. COGNIS™ 100-D CRT-D

Indications, Safety, and Warnings
<https://qrco.de/bgk2Hd>

**Boston
Scientific**

Advancing science for life™

Cardiology

300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

Medical Professionals:

1.800.CARDIAC (227.3422)

Patients and Families:

1.866.484.3268

© 2026 Boston Scientific Corporation
or its affiliates. All rights reserved.

CRM-373204-AC